Fig. 1.

The dual APL up-regulates CD8⁺CD28⁻ regulatory cells. (A and B) BALB/c mice were immunized with the myasthenogenic peptide p259-271 alone (▴) or concomitant with treatment with the dual APL (■). LN cells obtained from these mice were stained for CD8 and CD28 (A) or CD4 and CD25 (B) markers and analyzed by FACS at the indicated days after immunization and treatment. (C) The ratio between CD8⁺CD28⁺ and CD8⁺CD28⁻ was determined 10 days after immunization with p259-271 and treatment with the dual APL. C57BL/6 mice were immunized with TAChR and either treated or not with the dual APL. (D and E) LN cells were taken 10 days later and stained for CD8⁺CD28⁻ cells (D) or for Foxp3 out of the gated CD8⁺CD28⁻ cells (E). Results are from one representative experiment of three performed.